FrancophonIA/ELRC3.0 huggingface dataset:
English: • severe high blood pressure which cannot be controlled by blood pressure medicines; or a sudden severe rise in blood pressure,
Croatian: • u slučaju izrazito povišenog krvnog tlaka koji se ne može kontrolirati lijekovima ili naglog značajnog povišenja krvnog tlaka,
English: MVASI must be administered under the supervision of a physician experienced in the use of antineoplastic medicinal products.
Croatian: MVASI se mora primjenjivati pod nadzorom liječnika koji ima iskustva u primjeni antitumorskih lijekova.
English: Approximate 95% CI for difference of two rates using Hauck-Anderson method.
Croatian: Približno 95% CI za razliku između dviju stopa primjenom Hauck-Andersonove metode. log-rank test (stratificirani).
English: In an exploratory analysis, the extent of bevacizumab benefit on overall survival was less pronounced in the subgroup of patients who did not have adenocarcinoma histology.
Croatian: U eksploracijskoj analizi je utvrđeno da je opseg koristi liječenja lijekom bevacizumab u pogledu ukupnog preživljenja bio manje izražen u podskupini bolesnika koji histološki nisu imali adenokarcinom.
English: Tables 1 and 2 list adverse reactions associated with the use of bevacizumab in combination with different chemotherapy regimens in multiple indications.
Croatian: U Tablicama 1 i 2 navedene su nuspojave povezane s primjenom bevacizumaba u kombinaciji s različitim kemoterapijskim protokolima u većem broju indikacija.
English: Gastrointestinal (GI) perforations and Fistulae (see section 4.8) Patients may be at an increased risk for the development of gastrointestinal perforation and gall bladder perforation when treated with bevacizumab.
Croatian: Gastrointestinalne perforacije i fistule (vidjeti dio 4.8) Bolesnici mogu biti izloženi povećanom riziku od nastanka gastrointestinalnih perforacija i perforacija žučnog mjehura tijekom liječenja bevacizumabom.
English: Statistically significant improvements in progression-free survival and objective response rate were also observed (see table 8).
Croatian: Uočeno je i statistički značajno produljenje preživljenja bez progresije bolesti i povećanje stope objektivnog odgovora (vidjeti Tablicu 8).
English: Hazard ratio (95% CI) > 12 months (n = 282) Median
Croatian: Omjer hazarda (95% CI) > 12 mjeseci (n = 282) Medijan
English: Hypertensive encephalopathya
Croatian: hipertenzivna encefalopatijac
English: • abnormal urine test (protein in the urine),
Croatian: • poremećen nalaz mokraće (proteini u mokraći),
English: Further details on the study and the results are provided below.
Croatian: Dodatne pojedinosti i rezultati ispitivanja navedeni su u nastavku.
English: 3.7% of the overall randomised patient population had stage IIIB disease.
Croatian: 3,7% ukupne populacije randomiziranih bolesnica bilo je u stadiju bolesti IIIB.
English: Precautions to be taken before handling or administering the medicinal product For instructions on dilution of the medicinal product before administration, see section 6.6.
Croatian: Mjere opreza koje treba poduzeti prije rukovanja lijekom ili primjene lijeka Za upute o razrjeđivanju lijeka prije primjene vidjeti dio 6.6.
English: Bevacizumab in combination with interferon alfa-2a for the first-line treatment of advanced and/ or metastatic renal cell cancer (BO17705)
Croatian: Bevacizumab u kombinaciji s interferonom alfa-2a u prvoj liniji liječenja uznapredovalog i/ili metastatskog karcinoma bubrežnih stanica (BO17705)
English: • a negative effect on a woman's ability to have children (see the paragraphs below the list of side effects for further recommendations),
Croatian: • negativan učinak na ženinu plodnost (daljnje preporuke vidjeti u odjeljcima iza popisa nuspojava),
English: In the absence of PD, discontinuation of one component of study treatment in the erlotinib + bevacizumab arm did not lead to discontinuation of the other component of study treatment as specified in the study protocol.
Croatian: Ako nije došlo do progresije bolesti, prekid primjene jednog od lijekova uključenih u ispitivanje u skupini liječenoj erlotinibom + lijekom bevacizumab nije uzrokovao prekid primjene drugog lijeka uključenog u ispitivanje kao što je specificirano u protokolu ispitivanja.
English: Patients with untreated CNS metastases were routinely excluded from clinical trials with bevacizumab, based on imaging procedures or signs and symptoms.
Croatian: Bolesnici s neliječenim metastazama u središnjem živčanom sustavu (SŽS) bili su rutinski isključeni iz kliničkih ispitivanja s bevacizumabom na temelju dijagnostičkih snimaka ili znakova i simptoma.
English: Relative to the control arm; stratified hazard ratio.
Croatian: U odnosu na kontrolnu skupinu, stratificirani omjer rizika.
English: Before you are given MVASI or while you are being treated with MVASI:
Croatian: Prije nego primite MVASI ili tijekom liječenja lijekom MVASI:
English: Alternatively, a 1.25 mg/m2 dose could be administered over 30 minutes on days 1-5 every 3 weeks.
Croatian: Alternativno se mogla primjenjivati doza od 1,25 mg/m2 tijekom 30 minuta od 1. do 5. dana svaka 3 tjedna.
English: Patients with thromboembolic reactions ≤ grade 3 need to be closely monitored (NCI-CTCAE v.3).
Croatian: Bolesnike s tromboembolijskim reakcijama stupnja ≤ 3 treba pomno nadzirati (NCI-CTCAE v.3).
English: The observed increase in serum creatinine was not associated with a higher incidence of clinical manifestations of renal impairment in patients treated with bevacizumab.
Croatian: Primijećeno povećanje serumske razine kreatinina nije bilo povezano s većom incidencijom kliničkih manifestacija oštećenja bubrežne funkcije u bolesnika liječenih bevacizumabom.
English: The concentrate is a clear to slightly opalescent, colourless to slightly yellow liquid in a glass vial with a rubber stopper.
Croatian: Koncentrat je bistra do blago opalescentna, bezbojna do svijetložuta tekućina u staklenoj bočici s gumenim čepom.
English: Assessment of bevacizumab metabolism in rabbits following a single IV dose of 125I-bevacizumab indicated that its metabolic profile was similar to that expected for a native IgG molecule which does not bind VEGF.
Croatian: Procjena metabolizma bevacizumaba u kunića nakon jednokratne intravenske doze 125I-bevacizumaba pokazala je da je njegov metabolički profil sličan onome kakav bi se očekivao od prirodne molekule IgG-a koja ne vezuje VEGF.
English: Efficacy results for trials AVF0780g and AVF2192g
Croatian: Tablica 5. Rezultati djelotvornosti za ispitivanja AVF0780g i AVF2192g AVF0780g
English: • If you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.
Croatian: • ako imate ili ste imali aneurizmu (proširenje i slabljenje stijenke krvne žile) ili rascjep stijenke krvne žile.
English: Stopping your treatment with MVASI may stop the effect on tumour growth.
Croatian: Prekidom liječenja lijekom MVASI može prestati njegov učinak na rast tumora.
English: In clinical trials of metastatic carcinoma of the colon or rectum, there was no increased risk of postoperative bleeding or wound healing complications observed in patients who underwent major surgery 28-60 days prior to starting bevacizumab.
Croatian: U kliničkim ispitivanjima u indikaciji metastatskog karcinoma kolona ili rektuma nije zabilježen povećan rizik od postoperativnog krvarenja ili komplikacija pri zacjeljivanju rana u bolesnika koji su bili podvrgnuti većem kirurškom zahvatu 28 do 60 dana prije početka liječenja bevacizumabom.
English: The addition of erlotinib to bevacizumab did not result in an improvement in OS (HR = 1.764; p = 0.1789), duration of objective response (6.7 vs. 9.1 months) or time to symptom progression (HR = 1.172; p = 0.5076).
Croatian: Dodavanje erlotiniba bevacizumabu nije poboljšalo ukupno preživljenje (HR = 1,764; p = 0,1789), trajanje objektivnog odgovora (6,7 naprama 9,1 mjeseci) niti vrijeme do progresije simptoma (HR = 1,172; p = 0,5076).
English: • reduced blood supply to the brain or stroke,
Croatian: • smanjen dotok krvi u mozak ili moždani udar,
English: FOLFOX-4 or XELOX + placebo (n = 701)
Croatian: FOLFOX-4 ili XELOX + placebo (n = 701)
English: • bleeding, including bleeding in the lungs in patients with non-small cell lung cancer,
Croatian: • krvarenje, uključujući krvarenje u plućima u bolesnika s rakom pluća nemalih stanica,
English: Progression-free survival by time from last platinum therapy to recurrence
Croatian: Preživljenje bez progresije bolesti prema vremenu od posljednje terapije platinom do recidiva
English: • localised pus collection,
Croatian: • lokalizirano nakupljanje gnoja,
English: The pharmacokinetics of bevacizumab were evaluated in 152 children, adolescents and young adults (7 months to 21 years, 5.9 to 125 kg) across 4 clinical studies in paediatrics using a population pharmacokinetic model.
Croatian: Farmakokinetika bevacizumaba ispitana je u 152 djece, adolescenata i mlađih odraslih osoba (7 mjeseci do 21 godine; 5,9 do 125 kg) u 4 klinička ispitivanja u pedijatrijskoj populaciji uz pomoć populacijskog farmakokinetičkog modela.
English: MVASI is administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin or paclitaxel and topotecan.
Croatian: MVASI se primjenjuje u kombinaciji s jednim od sljedećih kemoterapijskih protokola: paklitakselom i cisplatinom ili paklitakselom i topotekanom.
English: Hazard ratio was estimated from Cox proportional hazards models stratified by the duration of platinum free-interval prior to enrolling onto this study per eCRF (electronic case report form) and secondary surgical debulking status Yes/No (Yes = randomised to undergo cytoreduction or randomised to not undergo cytoreduction; No = not a candidate or did not consent to cytoreduction).
Croatian: Omjer hazarda procjenjivao se Coxovim modelima proporcionalnog hazarda stratificiranima prema duljini razdoblja bez primjene platine prije uključivanja u ovo ispitivanje sukladno navodima u elektroničkim test listama ispitanika (engl. electronic case report form, eCRF) i statusu sekundarnog smanjenja tumorske mase kirurškim putem: Da/Ne (Da = randomizirana za citoredukciju ili randomizirana za neprovođenje citoredukcije; Ne = nije pogodna ili nije pristala na citoredukciju).
English: Eight hundred and twenty-nine patients were randomised (292 FOLFOX-4, 293 bevacizumab + FOLFOX-4 and 244 bevacizumab monotherapy).
Croatian: Randomizirano je 829 bolesnika (292 za protokol FOLFOX-4, 293 za bevacizumab + FOLFOX-4 i 244 za monoterapiju bevacizumabom).
English: With gross residual disease.
Croatian: Uz veliki rezidualni tumor.
English: b stratified by the duration of treatment free-interval prior to enrolling onto this study per the registration form, and secondary surgical debulking status Yes/No.
Croatian: b stratificirano prema duljini razdoblja bez primjene liječenja prije uključivanja u ovo ispitivanje sukladno navodima u registracijskim obrascima i statusu sekundarnog smanjenja tumorske mase kirurškim putem: Da/Ne.
English: • bleeding from the lower part of the large bowel,
Croatian: • krvarenje iz donjeg dijela debelog crijeva,
English: • symptoms that suggest changes in normal brain function (headaches, vision changes, confusion, or seizures), and high blood pressure,
Croatian: • simptomi koji upućuju na promjene u normalnom radu mozga (glavobolje, promjene vida, smetenost ili konvulzije) i visok krvni tlak,
English: • Seeing flashes of light with floaters, progressing to a loss of some of your vision,
Croatian: • pojava bljeskanja u vidnom polju s plutajućim česticama, koje napreduje do djelomičnog gubitka vida,
English: • decreased number of red cells in the blood,
Croatian: • smanjen broj crvenih krvnih stanica,
English: Efficacy results from study MO22224 Primary endpoint
Croatian: Tablica 22. Rezultati djelotvornosti za ispitivanje MO22224 Primarna mjera ishoda
English: Anti-tumour activity was not observed in two earlier studies among a total of 30 children aged > 3 years old with relapsed or progressive high-grade glioma when treated with bevacizumab and irinotecan (CPT 11).
Croatian: Antitumorska aktivnost nije opažena u dva ranija ispitivanja među ukupno 30 djece starije od 3 godine s relapsnim ili progresivnim gliomom visokog stupnja malignosti, kada su liječena bevacizumabom i irinotekanom (CPT-11).
English: Clinical trials have shown that transient increases in serum creatinine (ranging between 1.5-1.9 times baseline level), both with and without proteinuria, are associated with the use of bevacizumab.
Croatian: Klinička su ispitivanja pokazala da su prolazna povećanja serumske razine kreatinina (u rasponu od 1,5 do 1,9 puta iznad početne vrijednosti), koja su se javljala i uz istodobnu proteinuriju kao i bez nje, povezana s primjenom bevacizumaba.
English: The majority of the patients in each treatment arm (74% and 71%) had poorly differentiated (grade 3)
Croatian: U većine bolesnica u svakoj skupini (74% odnosno 71%) primarni su tumori na početku liječenja bili slabo diferencirani (stupnja 3).
English: • Redness of the eye, small particles or spots in your vision (floaters), eye pain,
Croatian: • crvenilo oka, male čestice ili mrlje u vidnom polju (plutajuće čestice), bol u oku,
English: % patients with objective response p-value
Croatian: % bolesnica s objektivnim odgovorom p-vrijednost
English: It is recommended that the treatment with MVASI in addition to erlotinib is continued until disease progression.
Croatian: Liječenje lijekom MVASI uz erlotinib preporučuje se nastaviti do progresije bolesti.
English: • redness, peeling, tenderness, pain, or blistering on the fingers or feet,
Croatian: • crvenilo, ljuštenje, osjetljivost, bol ili plikovi na prstima ili stopalima,
English: The efficacy data from trials AVF0780g and AVF2192g investigating bevacizumab in combination with 5-FU/FA chemotherapy are summarised in table 5.
Croatian: Podaci o djelotvornosti iz ispitivanja AVF0780g i AVF2192g, u kojima je ispitivana primjena bevacizumaba u kombinaciji s kemoterapijom 5-FU/FA, sažeti su u Tablici 5.
English: At baseline, most patients in both treatment arms had a GOG PS of 0 (CP: 82.4%: CPB; 80.7%) or 1 (CP: 16.7%: CPB; 18.1%).
Croatian: Na početku ispitivanja, većina bolesnica u obje liječene skupine imala je GOG funkcionalni status 0 (CP: 82,4%; CPB: 80,7%) ili 1 (CP: 16,7%; CPB: 18,1%).
English: MVASI has not been shown to reduce your ability to drive or to use any tools or machines.
Croatian: Nije se pokazalo da MVASI smanjuje sposobnost upravljanja vozilima i rukovanja alatima i strojevima.
English: A high proportion of patients (approximately 63% IFN/placebo; 55% bevacizumab/IFN) received a variety of non-specified post-trial anti-cancer therapies, including antineoplastic agents, which may have impacted the analysis of overall survival.
Croatian: Velik udio bolesnika (oko 63% za IFN/placebo; 55% za bevacizumab/IFN) je nakon završetka ispitivanja primao različite nespecificirane antitumorske terapije, uključujući antineoplastičke lijekove, što je moglo utjecati na analizu ukupnog preživljenja.
English: • MVASI may increase the risk of developing serious infections of the skin or deeper layers under the skin, especially if you had holes in the gut wall or problems with wound healing.
Croatian: • MVASI može povećati rizik od razvoja ozbiljnih infekcija kože ili dubljih potkožnih slojeva, osobito ako ste imali napuknuća u stijenci crijeva ili probleme sa zacjeljivanjem rana.
English: Post-marketing adverse reactions are included in both tables 1 and 2, where applicable.
Croatian: Nuspojave prijavljene nakon stavljanja lijeka u promet uključene su u Tablice 1 i 2 (kako je odgovarajuće).
English: Overall survival6
Croatian: Ukupno preživljenje6
English: The secondary endpoint of overall survival was not mature.
Croatian: Podaci za sekundarnu mjeru ishoda - ukupno preživljenje - nisu bili zreli.
English: Paclitaxel n = 115
Croatian: Paklitaksel n = 115
English: Tumour-associated haemorrhage was also seen rarely in other tumour types and locations, including cases of central nervous system (CNS) bleeding in patients with CNS metastases (see section 4.4).
Croatian: Krvarenja povezana s tumorom rijetko su primijećena i kod drugih vrsta tumora i drugih sijela, uključujući slučajeve krvarenja u središnjem živčanom sustavu u bolesnika s metastazama u SŽS-u (vidjeti dio 4.4).
English: Analyses of the clinical safety data suggest that the occurrence of hypertension and proteinuria with bevacizumab therapy are likely to be dose-dependent.
Croatian: Analize kliničkih podataka o sigurnosti primjene upućuju na to da pojava hipertenzije i proteinurije tijekom liječenja bevacizumabom vjerojatno ovisi o dozi.
English: Each pack of MVASI contains one vial.
Croatian: Svako pakiranje lijeka MVASI sadrži jednu bočicu.
English: • MVASI can increase the risk of developing a weak heart.
Croatian: • MVASI može povećati rizik od slabljenja srca.
English: However, patients who developed venous thrombosis while receiving therapy did not appear to have an increased rate of grade 3 or above bleeding when treated with a full dose of warfarin and bevacizumab concomitantly (NCI-CTCAE v.3).
Croatian: Međutim, bolesnici u kojih se tijekom liječenja razvila venska tromboza nisu imali povećanu stopu krvarenja stupnja 3 ili višeg stupnja pri istodobnom liječenju punom dozom varfarina i bevacizumabom (NCI-CTCAE v.3).
English: Trehalose dihydrate, sodium phosphate, polysorbate 20, water for injections.
Croatian: POPIS POMOĆNIH TVARI Trehaloza dihidrat, natrijev fosfat, polisorbat 20, voda za injekcije.
English: 5-fluorouracil IV bolus/infusion, each on days 1 and 2
Croatian: 5-fluorouracil i.v. bolus/infuzija, oboje 1. i 2. dana placebo ili bevacizumab
English: There is evidence suggesting that all grade (US National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE v.3]) proteinuria may be related to the dose.
Croatian: Dokazi upućuju na to da svi stupnjevi proteinurije (prema Općim terminološkim kriterijima za štetne događaje Nacionalnog instituta za rak [NCI-CTCAE v.3]) mogu ovisiti o dozi.
English: • AVF2192g: In combination with bolus 5-FU/FA for a total of 6 weeks of each 8 week-cycle (Roswell Park regimen) in patients who were not optimal candidates for first-line irinotecan treatment.
Croatian: • AVF2192g: u kombinaciji s bolusom 5-FU/FA kroz ukupno 6 tjedana tijekom svakog osmotjednog ciklusa (Roswell-Park protokol) u bolesnika koji nisu bili optimalni kandidati za primjenu irinotekana u prvoj liniji liječenja.
English: • fistula: abnormal tube-like connection between internal organs and skin or other tissues that are not normally connected, including connections between vagina and the gut in patients with cervical cancer.
Croatian: • fistula: neuobičajen spoj u obliku cjevčice između unutarnjih organa i kože ili drugih tkiva koja inače nisu povezana, uključujući spojeve između rodnice i probavnog sustava u bolesnica s rakom vrata maternice.
English: Treatment regimens in trial NO16966 (mCRC)
Croatian: Tablica 6. Protokoli liječenja u ispitivanju NO16966 (metastatski karcinom kolona ili rektuma)
English: • you are allergic (hypersensitive) to Chinese hamster ovary (CHO) cell products or to other recombinant human or humanised antibodies.
Croatian: • ako ste alergični (preosjetljivi) na proizvode stanica jajnika kineskog hrčka ili druga rekombinantna ljudska ili humanizirana protutijela.
English: Combination with platinum- or taxane-based therapies (see sections 4.4 and 4.8)
Croatian: Kombinacija s kemoterapijom na bazi platinskog spoja ili taksana (vidjeti dijelove 4.4 i 4.8)
English: Efficacy results from study BO17707 (ICON7) Progression-free survival
Croatian: Tablica 17. Rezultati djelotvornosti za ispitivanje BO17707 (ICON7) Preživljenje bez progresije bolesti
English: • It is possible that MVASI may cause bleeding in and around your brain.
Croatian: • Može se dogoditi da MVASI uzrokuje krvarenje u mozgu i oko mozga.
English: In study BO20924, bevacizumab exposure was generally lower compared to a typical adult patient at the same dose.
Croatian: U ispitivanju BO20924, izloženost bevacizumabu načelno je bila niža nego u tipičnog odraslog bolesnika pri istoj dozi.
English: Eye disorders Eye disorder, Lacrimation increased
Croatian: Poremećaji oka poremećaj oka, pojačano suzenje
English: An increased incidence of post-operative bleeding or wound healing complication occurring within 60 days of major surgery was observed if the patient was being treated with bevacizumab at the time of surgery.
Croatian: Zabilježena je povećana incidencija postoperativnog krvarenja ili komplikacija pri zacjeljivanju rana unutar 60 dana od većeg kirurškog zahvata ako je bolesnik primao bevacizumab u vrijeme zahvata.
English: In clinical trials, proteinuria has been reported within the range of 0.7% to 54.7% of patients receiving bevacizumab.
Croatian: U kliničkim je ispitivanjima proteinurija prijavljena u između 0,7% i 54,7% bolesnika koji su primali bevacizumab.
English: Patients receiving bevacizumab plus chemotherapy, with a history of arterial thromboembolism, diabetes or age greater than 65 years have an increased risk of developing arterial thromboembolic reactions during therapy.
Croatian: Bolesnici koji primaju bevacizumab zajedno s kemoterapijom i koji u anamnezi imaju arterijsku tromboemboliju, dijabetes ili su stariji od 65 godina, imaju povećan rizik za razvoj arterijskih tromboembolijskih reakcija tijekom liječenja.
English: • feeling weak and having no energy,
Croatian: • osjećaj slabosti i gubitak energije,
English: MVASI, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO)
Croatian: MVASI je u kombinaciji s karboplatinom i paklitakselom indiciran za prvu liniju liječenja odraslih bolesnica s uznapredovalim (International Federation of Gynecology and Obstetrics (FIGO) stadiji
English: The overall safety profile of bevacizumab is based on data from over 5,700 patients with various malignancies, predominantly treated with bevacizumab in combination with chemotherapy in clinical trials.
Croatian: Ukupan sigurnosni profil bevacizumaba temelji se na podacima prikupljenima u više od 5700 bolesnika s raznim malignim bolestima, koji su u kliničkim ispitivanjima uglavnom primali bevacizumab u kombinaciji s kemoterapijom.
English: However, somnolence and syncope have been reported with bevacizumab use (see table 1 in section 4.8).
Croatian: Međutim, pri primjeni bevacizumaba prijavljene su somnolencija i sinkopa (vidjeti tablicu 1 u dijelu 4.8).
English: IgGs are known to cross the placenta, and bevacizumab is anticipated to inhibit angiogenesis in the foetus, and thus is suspected to cause serious birth defects when administered during pregnancy.
Croatian: Poznato je da molekule IgG-a mogu proći kroz posteljicu, a pretpostavlja se da bevacizumab može spriječiti angiogenezu u fetusa te se stoga sumnja da bi mogao izazvati teške urođene mane ako se primjenjuje tijekom trudnoće.
English: MVASI infusions should not be administered or mixed with glucose solutions.
Croatian: Infuzije lijeka MVASI ne smiju se primjenjivati niti miješati s otopinama glukoze.
English: During the trial, of the patients who received trial treatment, 32.2% (136/422) of patients received 7-12 administrations of bevacizumab and 21.1% (89/422) of patients received 13 or more administrations of bevacizumab.
Croatian: Od bolesnika koji su tijekom ispitivanja primali ispitivani lijek, njih 32,2% (136/422) je primilo 7-12 aplikacija bevacizumaba, a 21,1% (89/422) 13 ili više aplikacija bevacizumaba.
English: • if you have or have had pain in the mouth, teeth and/or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth tell your doctor and dentist immediately.
Croatian: • ako osjećate ili ste osjećali bol u ustima, zubima i/ili čeljusti, ako imate otekline ili ranice u usnoj šupljini, ako osjećate utrnulost ili težinu u čeljusti, ili Vam se klima zub, odmah obavijestite svog liječnika i stomatologa.
English: 400 mg/m2 IV bolus, 600 mg/m2 IV 22 h
Croatian: 400 mg/m2 i.v. bolus, 600 mg/ m2 i.v. 22 h
English: p-value3,4 Objective response rate5
Croatian: p-vrijednost3,4 Objektivna stopa odgovora5